Laboratory Corporation of America Holdings (NYSE: LH), a prominent biotech company, has seen a variety of activities impacting its stock position, including stock acquisitions and disposals by numerous financial groups. The firm's stock reached a
52-week high of $239.65, testifying to its robust growth trend. Additionally,
Labcorp reported the finanicials for the
first quarter of 2024 and also settled a victorious bid for select assets of Invitae. Labcorp's
Acquisition of distinct assets of
BioReference Health's Diagnostics Business also enhanced the firm's stock gains. The company successfully delivered
EPS surpassing estimates on the Q2 earnings and met some disappointment on third quarter earnings with
EPS Miss. Despite these challenges,
LH raised its
2024 EPS view post Q1 Earnings. Additionaly, Labcorp announced
quarterly dividend and also started a collaboration with Hawthorne Effect to enhance clinical trials access in local communities.
Laboratory Corporation of America Holdings LH News Analytics from Wed, 26 Jun 2019 07:00:00 GMT to Sat, 23 Nov 2024 13:44:38 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor -2
